Genfit SA ( (GNFT) ) has issued an announcement.
GENFIT reported its full-year 2024 financial results, highlighting a net profit of €1.5 million and revenues of €67.0 million, driven by a milestone payment and royalties. The commercial launch of Iqirvo® in the U.S. and Europe marked a significant milestone, contributing to the company’s financial stability and strategic shift towards advancing its pipeline in Acute-on-Chronic Liver Failure (ACLF). The company also made substantial progress in its ACLF programs, utilizing real-world data to enhance understanding and treatment strategies, and initiated a transformative financial strategy to reinforce its financial outlook.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s stock score reflects significant financial challenges, particularly in profitability and cash flow. While the stock may be undervalued, negative technical trends and the absence of earnings call guidance contribute to a cautious outlook. Improvements in financial health and clearer strategic direction are needed for a more favorable assessment.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT S.A. is a late-stage biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases. The company has transitioned from a research and development focus to generating commercial revenues, particularly through its product Iqirvo®, which is used in the treatment of Primary Biliary Cholangitis (PBC).
YTD Price Performance: -4.93%
Average Trading Volume: 14,334
Technical Sentiment Signal: Buy
Current Market Cap: $173.5M
For detailed information about GNFT stock, go to TipRanks’ Stock Analysis page.